[
    [
        {
            "time": "2018-12-13",
            "original_text": "J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study",
            "features": {
                "keywords": [
                    "Tremfya",
                    "Cosentyx",
                    "Head-to-Head",
                    "Study"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-13",
            "original_text": "Pre-Market Most Active for Dec 13, 2018: GE, LPL, KEP, NVS, ERIC, SQQQ, QD, PKX, AMD, MRNS, QQQ, TQQQ",
            "features": {
                "keywords": [
                    "Pre-Market",
                    "Most Active",
                    "GE",
                    "LPL",
                    "KEP",
                    "NVS",
                    "ERIC",
                    "SQQQ",
                    "QD",
                    "PKX",
                    "AMD",
                    "MRNS",
                    "QQQ",
                    "TQQQ"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "healthcare",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-13",
            "original_text": "The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",
            "features": {
                "keywords": [
                    "Vivus",
                    "Supply Deal",
                    "Sandoz",
                    "Applied Genetic",
                    "Biogen"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-13",
            "original_text": "Novartis Reports EC Approval Of Xolair Syringe For Self-administration",
            "features": {
                "keywords": [
                    "Novartis",
                    "EC Approval",
                    "Xolair",
                    "Self-administration"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]